About I-Tech Investors Investerare News & Events Selektope® Contact I-Tech AB carries out a share issue of MSEK 44.1 ahead of listing on Nasdaq First North 02-05-2018 The Board of I-Tech AB ("I-Tech" or "The Company") has decided to carry out an equity issue of up to 2 150 000 shares and apply for listing of the Company's shares on Nasdaq First North. Read more Receive the latest I-Tech news Financial Reports Press releases I-Tech is heading for the world’s oceans About I-Tech I-Tech AB is a privately held bio-tech company based in Gothenburg, Sweden that owns all IP and regulatory rights to the antifouling agent Selektope® (generic name, medetomidine). I-Tech also controls the largest and most efficient source of medetomidine production. About the IPO I-Tech is facing significant growth and intends to implement a distribution issue of approximately SEK 40 million for listing on Nasdaq First North. The expected subscription period is during the first half of May with the first day of trading on 21 May, 2018. Events 2018 I Tech will be attending the following exhibitions in 2018: Posidonia Exhibition, Athens The International Congress on Marine Corrosion and Fouling, Florida SMM Hamburg Exhibition Recent press releases I-Tech AB carries out a share issue of MSEK 44.1 ahead of listing on Nasdaq First North 02-05-2018 The Board of I-Tech AB ("I-Tech" or "The Company") has decided to carry out an equity issue of up to 2 150 000 shares and apply for listing of the Company's shares on Nasdaq First North. Read more I-Tech AB signs deal for largest ever Selektope® order with Chugoku Marine Paints 19-03-2018 I-Tech AB, the Swedish developer of the bio-repellent antifouling ingredient Selektope®, has signed a significant supply agreement with one of the industry’s leading paint manufacturers representing the largest ever single order of the technology to-date. This deal represents yet another significant milestone for Selektope®, confirming the central position of coatings containing the ingredient in the… Read more I-Tech AB strengthens Selektope® supply chain with strategic acquisition 13-03-2018 Swedish bio-technology company I-Tech AB has today announced the strategic acquisition of manufacturing process technology and IP, for the production of medetomidine, from Cambrex Corporation (NYSE: CBM). The transaction consolidates the supply chain and improves I-Tech’s industrial capabilities. I-Tech AB has registered and patented medetomidine as a marine antifouling agent and is offering the active… Read more Biofouling during outfitting at South Korean shipyards drives high demand for Selektope® antifouling solution 21-02-2018 As global water temperatures increase, global ‘biofouling hotspots’ in subtropical/tropical areas are intensifying, exposing newbuildings at the world’s major shipyards to greater risk of hard fouling during the outfitting process. The effects of intense hard fouling on idle newbuilds can have great impact on a newly applied hull coating and on a vessel’s performance in… Read more Subscribe to receive our press releases Financial Reports Press releases I-Tech Social Media Hub Follow I-Tech on Twitter Selektope®Follow Selektope®@selektope· 8 May The very big business (still) of vessel performance - article from #Fathomworld @shiptech features #Selektope https://t.co/yQDSiDpqbj @fathom_news Reply on TwitterRetweet on TwitterLike on Twitter3Twitter Load More... Follow I-Tech on LinkedIn I-Tech AB is a public held bio-technology company based in Mölndal, Sweden that owns all IP and regulatory rights to the antifouling agent Selektope® (generic name, medetomidine). I-Tech also controls the largest and most efficient source of medetomidine production. Since 2006, I-Tech has successfully transformed the scientific invention of Selektope® into a commercially ready and available antifouling agent. You can also contact us directly via: info@i-tech.se or call +46 31 788 05 60. I-Tech AB c/o Astra Zeneca AB Pepparedsleden 1 SE- 431 83 Mölndal Sweden Subscribe to receive our latest news VIKTIG INFORMATION / IMPORTANT NOTICE Du har valt en webbsida med information som inte är avsedd att offentliggöras, publiceras eller distribueras, direkt eller indirekt, i eller till USA, Kanada, Australien, Nya Zeeland, Hongkong, Japan, Singapore eller Sydafrika. Genom att klicka ”Ja, jag accepterar” nedan accepterar du villkoren för tillträde till denna webbsida. Erbjudandet att teckna aktier i I-Tech AB (publ) i enlighet med villkoren i prospektet riktar sig inte till personer vars deltagande i erbjudandet kräver ytterligare prospekt, registreringsåtgärder eller andra åtgärder än de som följer av svensk rätt. Prospektet och andra till erbjudandet hänförliga handlingar får inte distribueras i något land där sådan distribution eller erbjudandet kräver ytterligare åtgärder än de som anges i föregående mening eller strider mot regler i sådant land. Nyemitterade aktier har inte registrerats och kommer inte att registreras i enlighet med United States Securities Act från 1933 i gällande lydelse, eller enligt tillämplig lag i Kanada, Australien, Nya Zeeland, Hongkong, Japan, Singapore eller Sydafrika och får därmed inte erbjudas eller överlåtas, direkt eller indirekt, till person med hemvist i något av dessa länder. Anmälan om teckning av aktier i strid med ovanstående kan komma att anses vara ogiltig och lämnas utan avseende. Tvist i anledning av erbjudandet, innehållet i prospektet och därmed sammanhängande rättsförhållanden ska avgöras av svensk domstol exklusivt. Svensk lag är exklusivt tillämplig på prospektet och på erbjudandet enligt prospektet. För att vara berättigad att ta del av informationen på följande webbsida ska du anses, om du tar del av följande webbsida, ha bekräftat och utfäst att (i) du har tagit del av och accepterar de villkor och restriktioner som angivits ovan samt (ii) du inte befinner dig i USA, Kanada, Australien, Nya Zeeland, Hongkong, Japan, Singapore eller Sydafrika. You are about to view a web page with information that is not intended for release, publication or distribution, directly or indirectly, in or into the United States of America, Canada, Australia, New Zealand, Hong Kong, Japan, Singapore or South Africa. By clicking "Yes, I accept" you accept the terms of use below. The offer according to the terms set out in the prospectus is not directed to people whose participation in the offer requires additional prospectuses, registration or measures other than those pursuant to Swedish law. The prospectus and other documents connected to the prospectus may not be distributed in any country in which the distribution or the offer requires measures as outlined above or are contrary to the regulations in such countries. The shares encompassed by the offer according to the prospectus have not been registered and will not be registered in accordance with the United States Securities Act from 1933 in its current wording or any provincial legislation in Canada, Australia, New Zealand, Hong Kong, Japan, Singapore or South Africa and may not be offered or sold, directly or indirectly, to persons domiciled in any of these countries or for the account of such a person. Application to subscribe for shares contrary to the above may be viewed as invalid and consequently ignored. Disputes arising from the offer, the contents of the prospectus and thereto connected legal matters shall be determined exclusively by a Swedish Court. Swedish law is exclusively applicable on the prospectus and the offer in accordance to the prospectus. In order to be eligible to view the information on the following web page, you shall be deemed, by accessing the following web page, to have confirmed and represented that (i) you have read and accepted the terms and restrictions set out above, and (ii) you are not located in the United States of America, Canada, Australia, New Zealand, Hong Kong, Japan, Singapore or South Africa. Ja, jag godkänner/Yes, I accept